Guillain–Barré Syndrome (GBS) and Other Immune-Mediated Neuropathies

  • Andrew R. Pachner


Guillain–Barré syndrome (GBS) is the most common serious immune-mediated disease affecting the peripheral nervous system (PNS). GBS is an acute diffuse illness affecting nerve roots and peripheral nerves, and occasionally the cranial nerves, often ascending from the feet over hours to days to the arms and sometimes bulbar muscles, resulting in motor weakness, and relatively sparing sensory functions; most patients who survive the acute paralysis recover completely within months. The disease was first described by the French neurologist, Landry, in 1859 (Inset 9.1).


Monoclonal Gammopathy Chronic Inflammatory Demyelinating Polyneuropathy Experimental Autoimmune Neuritis Miller Fisher Syndrome Bulbar Muscle 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Ho TW, Mishu B, Li CY, et al. Guillain-Barre ­syndrome in northern China. Relationship to Campylobacter jejuni infection and anti-glycolipid antibodies. Brain. 1995;118(Pt 3):597–605.PubMedCrossRefGoogle Scholar
  2. 2.
    McKhann GM, Griffin JW, Cornblath DR, Mellits ED, Fisher RS, Quaskey SA. Plasmapheresis and Guillain-Barre syndrome: analysis of prognostic ­factors and the effect of plasmapheresis. Ann Neurol. Apr 1988;23(4):347–53.PubMedCrossRefGoogle Scholar
  3. 3.
    McKhann GM, Cornblath DR, Ho T, et al. Clinical and electrophysiological aspects of acute paralytic disease of children and young adults in northern China. Lancet. 1991;338(8767):593–7.PubMedCrossRefGoogle Scholar
  4. 4.
    van der Meche FG, Schmitz PI, Dutch Guillain-Barre Study Group. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barre syndrome. N Engl J Med. 1992;326(17):1123–9.PubMedCrossRefGoogle Scholar
  5. 5.
    Hughes RA, Raphael JC, Swan AV, van Doorn PA. Intravenous immunoglobulin for Guillain-Barre ­syndrome. Cochrane Database Syst Rev. 2006(1):CD002063.Google Scholar
  6. 6.
    Halstead SK, Zitman FM, Humphreys PD, et al. Eculizumab prevents anti-ganglioside antibody-­mediated neuropathy in a murine model. Brain. May 2008;131(Pt 5):1197–208.PubMedGoogle Scholar
  7. 7.
    Koski CL, Baumgarten M, Magder LS, et al. Derivation and validation of diagnostic criteria for chronic inflammatory demyelinating polyneuropathy. J Neurol Sci. 2009;277(1–2):1–8.PubMedCrossRefGoogle Scholar
  8. 8.
    Eftimov F, Winer JB, Vermeulen M, de Haan R, van Schaik IN. Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev. 2009(1):CD001797.Google Scholar
  9. 9.
    Barohn RJ, Kissel JT, Warmolts JR, Mendell JR. Chronic inflammatory demyelinating polyradiculoneuropathy. Clinical characteristics, course, and recommendations for diagnostic criteria. Arch Neurol. 1989;46(8):878–84.PubMedCrossRefGoogle Scholar
  10. 10.
    Yu RK, Usuki S, Ariga T. Ganglioside molecular mimicry and its pathological roles in Guillain-Barre syndrome and related diseases. Infect Immun. Dec 2006;74(12):6517–27.PubMedCrossRefGoogle Scholar
  11. 11.
    Ilyas AA, Gu Y, Dalakas MC, Quarles RH, Bhatt S. Induction of experimental ataxic sensory neuronopathy in cats by immunization with purified SGPG. J Neuroimmunol. Jan 2008;193(1–2):87–93.PubMedCrossRefGoogle Scholar
  12. 12.
    Logina I, Donaghy M. Diphtheritic polyneuropathy: a clinical study and comparison with Guillain-Barre syndrome. J Neurol Neurosurg Psychiatry. Oct 1999;67(4):433–8.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  • Andrew R. Pachner
    • 1
  1. 1.Department of Neurology and Neuroscience New Jersey Medical SchoolUniversity of Medicine and Dentistry of New JerseyNewarkUSA

Personalised recommendations